Gyre Therapeutics, Inc. (GYRE)
Nasdaq: GYRE · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2002
Grade5.2
◀ Past 4.5● Present 5.9▶ Future 4.9
Who owns Gyre Therapeutics, Inc.
As filed with the SECHolders of 5% or more
3
GNI USA, Inc. holds 69.1% of Common Stock, par value $0.001 per share, as its SCHEDULE 13D/A filed May 6, 2026 says.
Directors and officers
15
report now, of 35 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
GNI USA, Inc.
SCHEDULE 13D/A · filed May 6, 2026 · Common Stock, par value $0.001 per share
Ying Luo
SCHEDULE 13D/A · filed May 6, 2026 · Common Stock, par value $0.001 per share
Songjiang Ma
SCHEDULE 13D/A · filed May 7, 2026 · Common Stock, par value $0.001 per share
What GYRE reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Cullgen Capital Stock
A company bought · acquisition · owns, named in the 10-K filed Mar 13, 2026
G C Biopharma Corp
A company bought · acquisition · owns, named in the 10-K filed Mar 13, 2026
9 subsidiaries in 4 countries, from the list filed with the 10-K filed Mar 13, 2026.
Insider tradesForm 4
18sales
0purchases
2sales on a scheduled plan
2people selling
$1.0Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 44 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Ye Weiguo | Chief Operating Officer | 16 | $900,000 | 0 | 0 | $0 |
| Luo Ying | Chief Executive Officer | 2 | $100,000 | 2 | 0 | $0 |